

Initiator Pharma carries out a directed share issue to a financial advisor

The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808, ("Initiator" or the "Company") has today resolved to carry out a directed share issue to a financial advisor in connection with the recently completed rights issue.

Today the Company's Board of Directors have decided to increase the Company's share capital by a total of nominally DKK 34,999.965 divided into 333,333 shares (the "New Shares") of nominally DKK 0.105 as a result of a directed share issue to one of the financial advisors in connection with the Company's recently completed rights issue. The New Shares have been issued without pre-emption rights for the existing shareholders subject to the board authorisation in article 4b in the Company's articles of association.

The capital increase in connection with the subscription of New Shares by the private investor amounts to nominally DKK 34,999.965 corresponding to 333,333 shares of nominally DKK 0.105. The New Shares have been subscribed for by cash contribution at a price of SEK 7.5 per share (corresponding to DKK 5.1825 per share) and the deadline for payment of the shares is 7 days from today. As a result, the Company's expects gross proceeds of approximately DKK 1.7 million. In the view of the Board of Directors, the price per share of SEK 7.5 reflects the current market value.

The New Shares will upon issuance be subject to the same rights as existing shares under the Company's articles of association and is expected to be admitted to trading on Nasdaq First North Growth Market under the existing ISIN code DK0060775872 once the capital increase has been registered with the Danish Business Authority.

After the capital increase, the total nominal value of the Company's share capital will amount to nominally DKK 4,924,338.4 divided into 46,898,461 shares of nominally DKK 0.105 each corresponding to 46,898,461 votes.

The Company will send out a new company announcement when the capital increase has been registered with the Danish Business Authority.

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma's pipeline consists of three clinical programs - the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition.

Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB, with email address certifiedadviser@redeye.se and phone number +46 8 121 576 90, is the company's Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

Initiator Pharma carries out a directed share issue to a financial advisor